For the clinically challenged (3putt raises his hand), some Sunday morning refresher on ORR for our trial.
ORR:
I further asked so what's a good target for ORR in mCRC:
I suspect we're a skoshi early for significant numbers in the April 21 readout (abstract available 17 April in the program planner), but Dr. Pashtoon is pumped for the conference. If he's pumped, then I'm pumped.
ORR:
Quote:Objective Response Rate (ORR) is the proportion of patients in a clinical trial whose cancer shrinks or disappears after treatment, combining both complete response (CR) and partial response (PR). It is a key efficacy endpoint for evaluating cancer therapies and often used for regulatory approvals, typically measured using standardized criteria like RECIST (Response Evaluation Criteria in Solid Tumors).Key Aspects of
{ORR% } =100 * {Number of patients with CR + PR}/{Total number of evaluable patients}
I further asked so what's a good target for ORR in mCRC:
Quote:In summary, a high ORR in modern colorectal cancer clinical trials is typically >30–40%, particularly when targeting specific mutations or employing combination immunotherapies in refractory settings.
I suspect we're a skoshi early for significant numbers in the April 21 readout (abstract available 17 April in the program planner), but Dr. Pashtoon is pumped for the conference. If he's pumped, then I'm pumped.
21
